Benzinga | Nov 5, 2020 09:05AM EST

BeiGene Highlights Presentation Of Data On BRUKINSA, Tislelizumab At Upcoming American Society Of Hematology Dec. 5-7

BeiGene, Ltd. (NASDAQ:BGNE, HKEX: 06160))), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that clinical data on its BTK inhibitor BRUKINSA(r) (zanubrutinib) and non-clinical data on its anti-PD-1 antibody tislelizumab will be presented in an oral presentation and four posters at the 62nd American Society for Hematology (ASH) Annual Meeting, taking place virtually on December 5-8, 2020.

BeiGene is co-sponsoring a satellite symposium entitled Addressing the Medical Need in CLL: How BTK Inhibitors Are Improving Outcomes, to be held on Friday, December 4 at 3:00 p.m. PT; registration for the symposium can be accessed at https://events.clinicaloptions.com/oncology/event-list/event/?id=a95f3d53-49d8-ea11-80f9-005056943d50.

Oral Presentation:

Efficacy and Safety of Zanubrutinib in Patients with Relapsed/Title: Refractory Marginal Zone Lymphoma: Initial Results of the MAGNOLIA (BGB-3111-214) Trial

Publication 339#:

Session 623. Mantle Cell, Follicular, and Other Indolent B-CellTitle: Lymphoma?Clinical Studies: Clinical studies in Waldenstro:m?s Macroglobulinemia, Marginal Zone Lymphoma and Hairy Cell Leukemia

Date and Sunday, December 6, 2020 at 10:15 a.m. PTTime:

Presenter: Stephen Opat, FRACP, FRCPA, MBBS, Monash University, Australia

Poster Presentations:

Safety and Efficacy of the Bruton Tyrosine Kinase InhibitorTitle: Zanubrutinib (BGB-3111) in Patients with Waldenstro:m Macroglobulinemia from a Phase 2 Trial

Publication 2940#:

Session 623. Mantle Cell, Follicular, and Other Indolent B-CellTitle: Lymphoma?Clinical Studies: Poster III

Date: Monday, December 7, 2020 at 7:00 a.m. PT

Presenter: Gang An, M.D., Ph.D., Chinese Academy of Medical Sciences, Blood Diseases Hospital, China

Phase 2 Study of Zanubrutinib in Patients with Relapsed/Title: Refractory B-Cell Malignancies Intolerant to Ibrutinib/ Acalabrutinib

Publication 2947#:

Session 623. Mantle Cell, Follicular, and Other Indolent B-CellTitle: Lymphoma?Clinical Studies: Poster III

Date: Monday, December 7, 2020 at 7:00 a.m. PT

Presenter: Mazyar Shadman, M.D., MPH, Fred Hutchinson Cancer Research Center, University of Washington

Efficacy and Safety of Zanubrutinib in Patients withTitle: Treatment-Nai:ve (TN) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) with del(17p): Follow-up Results from Arm C of the SEQUOIA (BGB-3111-304) Trial

Publication 1306#:

Session 642. CLL: Therapy, excluding Transplantation: Poster ITitle:

Date: Saturday, December 5, 2020 at 7:00 a.m. PT

Presenter: Jennifer R. Brown, M.D., Ph.D., Dana-Farber Cancer Institute

Title: Tumor Microenvironment Associated with Complete Response to Tislelizumab Monotherapy in Relapsed/Refractory Classical Hodgkin Lymphoma Reveals a Potentially Different Mechanism of Action

Publication 1116#:

Session 622. Lymphoma Biology?Non-Genetic Studies: Poster ITitle:

Date: Saturday, December 5, 2020 at 7:00 a.m. PT

Presenter: Yuqin Song, M.D., Ph.D., Peking University Cancer Hospital & Institute (Beijing Cancer Hospital), China